argenex SE $ARGX Shares Purchased by HighVista Strategies LLC

HighVista Strategies LLC boosted its holdings in shares of argenex SE (NASDAQ:ARGX) by 68.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,068 shares of the company’s stock after purchasing an additional 1,653 shares during the period. HighVista Strategies LLC’s holdings in argenex were worth $3,000,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Ameriflex Group Inc. acquired a new stake in shares of argenex during the third quarter worth about $32,000. Bessemer Group Inc. grew its holdings in shares of argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares during the last quarter. MAI Capital Management increased its position in argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares during the period. Mather Group LLC. purchased a new stake in argenex during the 3rd quarter valued at approximately $50,000. Finally, Rossby Financial LCC raised its stake in argenex by 115.2% during the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock valued at $54,000 after acquiring an additional 38 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Performance

argenex stock opened at $700.45 on Monday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company has a market capitalization of $43.34 billion, a price-to-earnings ratio of 35.88, a PEG ratio of 1.16 and a beta of 0.38. The stock has a fifty day moving average of $804.00 and a two-hundred day moving average of $817.49.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.05 by $1.97. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the topic of several analyst reports. Stifel Nicolaus lifted their target price on argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Royal Bank Of Canada decreased their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Finally, Citigroup lowered their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex currently has a consensus rating of “Moderate Buy” and an average target price of $999.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.